Enliven Therapeutics (NASDAQ:ELVN) COO Anish Patel Sells 6,667 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 6,667 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $17.40, for a total value of $116,005.80. Following the completion of the transaction, the chief operating officer owned 269,974 shares of the company’s stock, valued at approximately $4,697,547.60. This trade represents a 2.41% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Anish Patel also recently made the following trade(s):

• On Tuesday, October 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.10, for a total transaction of $134,006.70.
• On Monday, September 8th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.24, for a total value of $134,940.08.

Enliven Therapeutics Trading Up 1.3%

Shares of NASDAQ:ELVN traded up $0.26 during midday trading on Thursday, reaching $20.56. 47,432 shares of the company were exchanged, compared to its average volume of 416,569. The business’s fifty day moving average is $20.19 and its two-hundred day moving average is $20.04. Enliven Therapeutics, Inc. has a one year low of $13.30 and a one year high of $27.20. The stock has a market cap of $1.22 billion, a PE ratio of -10.26 and a beta of 0.80.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Wednesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.11. As a group, sell-side analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $41.20.

Institutional Trading of Enliven Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. increased its holdings in Enliven Therapeutics by 4.3% in the second quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock valued at $440,000 after buying an additional 913 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares during the last quarter. Quantbot Technologies LP grew its holdings in Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after buying an additional 1,434 shares during the period. Legal & General Group Plc raised its stake in Enliven Therapeutics by 4.8% during the third quarter. Legal & General Group Plc now owns 33,765 shares of the company’s stock worth $691,000 after purchasing an additional 1,540 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Enliven Therapeutics by 8.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock worth $428,000 after buying an additional 1,693 shares during the period. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.